OPK Opko Health Inc.

2.4
-0.01  -0%
Previous Close 2.41
Open 2.41
Price To Book 0.82
Market Cap 1478697115
Shares 616,123,798
Volume 6,731,012
Short Ratio
Av. Daily Volume 4,938,920

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data March 21, 2019 met primary endpoint. Data to be presented at ADA meeting June 7-11, 2019. Will evaluate Phase 3 options.
OPK88003
Obesity and diabetes
Phase 2a trial planned for 2H 2018.
OPK88002
Pruritus in Stage 5 CKD patients undergoing dialysis
Phase 2a trial planned for 2H 2018.
OPK88001
Dravet Syndrome
Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b trial suspension announced January 31, 2019.
OPK88004
Benign Prostatic Hyperplasia (BPH)
Phase 2 trial initiation announced September 4, 2018. Data from first cohort due 2019.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 data due YE 2019.
hGH-CTP
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 ongoing as of September 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 1H 2018.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV

Latest News

  1. BioReference Laboratories Recognized by Forbes as Best Large Employer of 2019
  2. Weekly CEO Buys Highlight
  3. Weekly Top Insider Buys Highlight for the Week of April 12
  4. OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial
  5. See what the IHS Markit Score report has to say about OPKO Health Inc.
  6. Read This Before Selling OPKO Health, Inc. (NASDAQ:OPK) Shares
  7. Analysts Drastically Reduced Target Price for Opko Health in March
  8. OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial
  9. Edited Transcript of OPK earnings conference call or presentation 27-Feb-19 9:30pm GMT
  10. OPKO Health (OPK) Reports Loss in Q4, Misses on Revenues
  11. OPKO Health Inc (OPK) Files 10-K for the Fiscal Year Ended on December 31, 2018
  12. Who OPKO Health Is Tanking Today
  13. Watch These Four Healthcare Stocks Set The Pace on Thursday
  14. Opko Health Inc (OPK) Q4 2018 Earnings Conference Call Transcript
  15. OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results
  16. OPKO Health to Announce Fourth Quarter 2018 Financial Results on February 27, 2019
  17. Research Report Identifies Cognizant Technology Solutions, OPKO Health, MedEquities Realty Trust, AXT, Red Robin Gourmet Burgers, and Dorian LPG with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement